Expand SRPT Menu
SRPT MENU

SRPT Latest Press Releases

-- July 29, 2026 --

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 5:00 PM

-- July 27, 2026 --

Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer Business Wire 8:30 AM

-- July 22, 2026 --

Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results Business Wire 8:30 AM

-- July 13, 2026 --

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Sarepta Therapeutics, Inc. (SRPT) Globe Newswire 9:46 AM

-- June 30, 2026 --

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:25 PM
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45 and VYONDYS 53 Business Wire 8:30 AM

-- June 3, 2026 --

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion Globe Newswire 8:30 AM

-- June 1, 2026 --

Sarepta Therapeutics to Participate in Upcoming Investor Conferences Business Wire 4:30 PM

-- May 13, 2026 --

Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference Business Wire 4:30 PM

-- May 6, 2026 --

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments Business Wire 4:05 PM

-- April 22, 2026 --

Sarepta Therapeutics to Announce First Quarter 2026 Financial Results Business Wire 8:30 AM

-- April 20, 2026 --

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech Globe Newswire 8:30 AM

-- March 31, 2026 --

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:05 PM

-- March 25, 2026 --

Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 Business Wire 8:05 AM

-- March 24, 2026 --

Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 Business Wire 4:05 PM

-- March 19, 2026 --

Sarepta Provides Regulatory Update on AMONDYS 45 and VYONDYS 53 Business Wire 8:30 AM

-- March 16, 2026 --

Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne Business Wire 8:33 AM
Market Data Delayed 15 Minutes